StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE total assets

Total assets on the balance sheet at the end of each period.

Viridian Therapeutics, Inc.\DE's total assets was $1.10B at Jun 30, 2026. For fiscal 2025 it was $899.42M, up 21.1% from the year before. Over ten years it grew 52.9% a year on average. The highest annual figure on record is $899.42M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$899.42M+21.1%
FY2024Dec 31, 2024$742.40M+51.4%
FY2023Dec 31, 2023$490.42M+12.7%
FY2022Dec 31, 2022$435.09M+113.6%
FY2021Dec 31, 2021$203.71M+55.2%
FY2020Dec 31, 2020$131.26M+333.7%
FY2019Dec 31, 2019$30.26M-54.3%
FY2018Dec 31, 2018$66.15M+26.0%
FY2017Dec 31, 2017$52.48M+112.0%
FY2016Dec 31, 2016$24.76M+91.9%
FY2015Dec 31, 2015$12.90M+59.5%
FY2014Dec 31, 2014$8.09M+120.2%
FY2013Dec 31, 2013$3.67M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.10B+88.4%
Q1 FY2026Mar 31, 2026$789.02M+19.4%
Q4 FY2025Dec 31, 2025$899.42M+21.1%
Q3 FY2025Sep 30, 2025$577.14M-25.2%
Q2 FY2025Jun 30, 2025$582.32M-0.6%
Q1 FY2025Mar 31, 2025$660.98M+4.9%
Q4 FY2024Dec 31, 2024$742.40M+51.4%
Q3 FY2024Sep 30, 2024$771.90M+134.8%
Q2 FY2024Jun 30, 2024$585.66M+66.6%
Q1 FY2024Mar 31, 2024$630.38M+63.0%
Q4 FY2023Dec 31, 2023$490.42M+12.7%
Q3 FY2023Sep 30, 2023$328.76M-25.4%
Q2 FY2023Jun 30, 2023$351.47M+107.0%
Q1 FY2023Mar 31, 2023$386.64M+111.1%
Q4 FY2022Dec 31, 2022$435.09M+113.6%
Q3 FY2022Sep 30, 2022$440.58M+99.2%
Q2 FY2022Jun 30, 2022$169.81M+43.7%
Q1 FY2022Mar 31, 2022$183.17M+49.1%
Q4 FY2021Dec 31, 2021$203.71M+55.2%
Q3 FY2021Sep 30, 2021$221.21M+573.7%
Q2 FY2021Jun 30, 2021$118.20M+253.0%
Q1 FY2021Mar 31, 2021$122.83M+214.6%
Q4 FY2020Dec 31, 2020$131.26M+333.7%
Q3 FY2020Sep 30, 2020$32.83M-15.4%
Q2 FY2020Jun 30, 2020$33.49M-31.4%
Q1 FY2020Mar 31, 2020$39.05M-28.9%
Q4 FY2019Dec 31, 2019$30.26M-54.3%
Q3 FY2019Sep 30, 2019$38.81M-49.3%
Q2 FY2019Jun 30, 2019$48.78M-40.4%
Q1 FY2019Mar 31, 2019$54.95M-36.8%
Q4 FY2018Dec 31, 2018$66.15M+26.0%
Q3 FY2018Sep 30, 2018$76.55M+62.6%
Q2 FY2018Jun 30, 2018$81.89M+63.7%
Q1 FY2018Mar 31, 2018$86.99M+50.5%
Q4 FY2017Dec 31, 2017$52.48M+112.0%
Q3 FY2017Sep 30, 2017$47.08M+524.3%
Q2 FY2017Jun 30, 2017$50.03M–
Q1 FY2017Mar 31, 2017$57.79M–
Q4 FY2016Dec 31, 2016$24.76M–
Q3 FY2016Sep 30, 2016$7.54M–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?